216 related articles for article (PubMed ID: 9188099)
21. Analysis of the contribution of receptor subdomains to the cooperative binding and internalization of transforming growth factor-beta (TGF-beta) type I and type II receptors.
Zwaagstra JC; Collins C; Langlois MJ; O'Connor-McCourt MD
Exp Cell Res; 2008 Aug; 314(14):2553-68. PubMed ID: 18598696
[TBL] [Abstract][Full Text] [Related]
22. The serine/threonine transmembrane receptor ALK2 mediates Müllerian inhibiting substance signaling.
Visser JA; Olaso R; Verhoef-Post M; Kramer P; Themmen AP; Ingraham HA
Mol Endocrinol; 2001 Jun; 15(6):936-45. PubMed ID: 11376112
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of protein tyrosine kinases attenuates increases in expression of transforming growth factor-beta isoforms and their receptors following arterial injury.
Ward MR; Agrotis A; Kanellakis P; Dilley R; Jennings G; Bobik A
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2461-70. PubMed ID: 9409216
[TBL] [Abstract][Full Text] [Related]
24. Transforming growth factor-beta (TGF-beta)-induced down-regulation of cyclin A expression requires a functional TGF-beta receptor complex. Characterization of chimeric and truncated type I and type II receptors.
Feng XH; Filvaroff EH; Derynck R
J Biol Chem; 1995 Oct; 270(41):24237-45. PubMed ID: 7592630
[TBL] [Abstract][Full Text] [Related]
25. GS domain mutations that constitutively activate T beta R-I, the downstream signaling component in the TGF-beta receptor complex.
Wieser R; Wrana JL; Massagué J
EMBO J; 1995 May; 14(10):2199-208. PubMed ID: 7774578
[TBL] [Abstract][Full Text] [Related]
26. Structural and functional evidence for a singular repertoire of BMP receptor signal transducing proteins in the lophotrochozoan Crassostrea gigas suggests a shared ancestral BMP/activin pathway.
Herpin A; Lelong C; Becker T; Rosa F; Favrel P; Cunningham C
FEBS J; 2005 Jul; 272(13):3424-40. PubMed ID: 15978047
[TBL] [Abstract][Full Text] [Related]
27. GH3 pituitary tumor cells contain heteromeric type I and type II receptor complexes for transforming growth factor beta and activin-A.
Moustakas A; Takumi T; Lin HY; Lodish HF
J Biol Chem; 1995 Jan; 270(2):765-9. PubMed ID: 7822308
[TBL] [Abstract][Full Text] [Related]
28. Different domains regulate homomeric and heteromeric complex formation among type I and type II transforming growth factor-beta receptors.
Rechtman MM; Nakaryakov A; Shapira KE; Ehrlich M; Henis YI
J Biol Chem; 2009 Mar; 284(12):7843-52. PubMed ID: 19147499
[TBL] [Abstract][Full Text] [Related]
29. Predominant intracellular localization of the type I transforming growth factor-beta receptor and increased nuclear accumulation after growth arrest.
Zwaagstra JC; Guimond A; O'Connor-McCourt MD
Exp Cell Res; 2000 Jul; 258(1):121-34. PubMed ID: 10912794
[TBL] [Abstract][Full Text] [Related]
30. Growth differentiation factor-9 signaling is mediated by the type I receptor, activin receptor-like kinase 5.
Mazerbourg S; Klein C; Roh J; Kaivo-Oja N; Mottershead DG; Korchynskyi O; Ritvos O; Hsueh AJ
Mol Endocrinol; 2004 Mar; 18(3):653-65. PubMed ID: 14684852
[TBL] [Abstract][Full Text] [Related]
31. Bone morphogenetic protein receptor complexes on the surface of live cells: a new oligomerization mode for serine/threonine kinase receptors.
Gilboa L; Nohe A; Geissendörfer T; Sebald W; Henis YI; Knaus P
Mol Biol Cell; 2000 Mar; 11(3):1023-35. PubMed ID: 10712517
[TBL] [Abstract][Full Text] [Related]
32. Ligand-induced dimerization of the extracellular domain of the TGF-beta receptor type II.
Letourneur O; Goetschy JF; Horisberger M; Grütter MG
Biochem Biophys Res Commun; 1996 Jul; 224(3):709-16. PubMed ID: 8713111
[TBL] [Abstract][Full Text] [Related]
33. Assignment of transforming growth factor beta1 and beta3 and a third new ligand to the type I receptor ALK-1.
Lux A; Attisano L; Marchuk DA
J Biol Chem; 1999 Apr; 274(15):9984-92. PubMed ID: 10187774
[TBL] [Abstract][Full Text] [Related]
34. Reduction in transforming growth factor-beta type II receptor in mouse lung carcinogenesis.
Jakowlew SB; Moody TW; You L; Mariano JM
Mol Carcinog; 1998 May; 22(1):46-56. PubMed ID: 9609100
[TBL] [Abstract][Full Text] [Related]
35. Cloning of a novel type II serine/threonine kinase receptor through interaction with the type I transforming growth factor-beta receptor.
Kawabata M; Chytil A; Moses HL
J Biol Chem; 1995 Mar; 270(10):5625-30. PubMed ID: 7890683
[TBL] [Abstract][Full Text] [Related]
36. Expression of transforming growth factor-beta receptor type I and type II in rat ventral prostate and Dunning R3327 PAP adenocarcinoma in response to castration and oestrogen treatment.
Wikström P; Bergh A; Damber JE
Urol Res; 1997; 25(2):103-11. PubMed ID: 9144876
[TBL] [Abstract][Full Text] [Related]
37. Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D.
Wang Z; Guo L; Song Y; Zhang Y; Lin D; Hu B; Mei Y; Sandikin D; Liu H
Cancer Immunol Immunother; 2017 Apr; 66(4):537-548. PubMed ID: 28184969
[TBL] [Abstract][Full Text] [Related]
38. Signaling activity of transforming growth factor beta type II receptors lacking specific domains in the cytoplasmic region.
Wieser R; Attisano L; Wrana JL; Massagué J
Mol Cell Biol; 1993 Dec; 13(12):7239-47. PubMed ID: 8246946
[TBL] [Abstract][Full Text] [Related]
39. Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.
Clarke TR; Hoshiya Y; Yi SE; Liu X; Lyons KM; Donahoe PK
Mol Endocrinol; 2001 Jun; 15(6):946-59. PubMed ID: 11376113
[TBL] [Abstract][Full Text] [Related]
40. Determination of type I receptor specificity by the type II receptors for TGF-beta or activin.
Ebner R; Chen RH; Lawler S; Zioncheck T; Derynck R
Science; 1993 Nov; 262(5135):900-2. PubMed ID: 8235612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
